Full-Time

Principal Scientist

Analytical Development, Oligo and Small Molecule

Praxis Precision Medicines

Praxis Precision Medicines

201-500 employees

Clinical-stage biopharma developing CNS therapies

Compensation Overview

$165k - $185k/yr

+ Bonus + Equity Incentives + ESPP

Remote in USA

Remote

Willing to travel as needed.

Master's

Category
Biology & Biotech (1)

Get referred to Praxis Precision Medicines

See people who can refer or advise you

Requirements
  • Advanced degree (PhD preferred; Master’s with significant industry experience considered) in Analytical Chemistry or related discipline with 5–7+ years of industry experience
  • Strong industry experience in analytical development for oligonucleotide drug substances and/or drug products required
  • Experience supporting small molecule drug substances and solid oral dosage forms strongly preferred
  • Deep knowledge of analytical techniques relevant to oligonucleotides, including impurity characterization, stability assessment, and GMP control strategies
  • Strong understanding of US and EU current Good Manufacturing Practice requirements and analytical best practices for drug substance and drug product development
  • Experience supporting CMC development across multiple stages of development, including regulatory submissions, validation, and commercialization activities
  • Experience managing external Contract Research Organizations and Contract Manufacturing Organizations analytical networks and building productive technical partnerships
  • Strong working knowledge of quality systems, reference standards, stability programs, and compendial testing requirements
Responsibilities
  • Serve as Analytical Lead across Chemistry, Manufacturing, and Controls programs, with primary responsibility for oligonucleotide analytical development activities and support for small molecule programs
  • Lead analytical method development, qualification, validation, transfer, and GMP testing activities across internal teams and external partners
  • Drive technical troubleshooting, data interpretation, method lifecycle management, and review of analytical documentation including validation reports, stability reports, specifications, and Certificates of Analysis
  • Design and implement phase-appropriate analytical control strategies, specifications, and stability programs for oligonucleotide and small molecule drug substances and drug products
  • Direct and manage CRO/CMO analytical partners to ensure high-quality execution, strong communication, and continuous operational improvement
  • Collaborate cross-functionally to strengthen CMC operations, improve processes, and establish scalable technical and business practices across the analytical function
  • Contribute strategic and technical expertise to support regulatory filings, commercialization readiness, and ongoing product lifecycle management
Praxis Precision Medicines

Praxis Precision Medicines

View

Praxis Precision Medicines develops therapies for central nervous system (CNS) disorders, with a focus on conditions caused by neuronal imbalance and genetic epilepsies. Its products aim to restore balance in CNS networks by applying genetic epilepsy insights, progressing through clinical development toward potential commercialization. What sets Praxis apart is its commitment to patient-guided development, incorporating patient and caregiver needs into therapy design, alongside strategic partnerships with other healthcare entities. The company's goal is to deliver effective CNS treatments to patients and caregivers and advance collaborations that support clinical development and eventual market access.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2015

Get referred to Praxis Precision Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 FDA mid-cycle meetings showed no major safety issues and no advisory committees.
  • Praxis ended June 30, 2026 with $1.4 billion cash, funding operations into 2028.
  • Commercial hiring and launch systems are already underway for ulixacaltamide and relutrigine.

What critics are saying

  • Vormatrigine missed POWER1 primary endpoint on June 1, 2026, and paused POWER2 enrollment.
  • Relutrigine gained a December 27, 2026 delay after FDA requested major amendment review.
  • An $8.4 billion valuation on pre-commercial assets leaves huge downside if approvals slip.

What makes Praxis Precision Medicines unique

  • Praxis links genetic neuroscience with FDA-backed precision drugs for rare epilepsies and tremor.
  • Ulixacaltamide is first Phase 3 positive essential tremor program, strengthening category leadership.
  • Relutrigine targets SCN2A and SCN8A DEEs, aiming at first-approved therapy status.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Stock Options

Company Equity

Performance Bonus

Unlimited Paid Time Off

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
May 17th, 2026
FDA accepts Praxis Precision Medicines NDAs amid $92.6M Q1 loss and cash runway to 2028

Praxis Precision Medicines reported a first-quarter 2026 net loss of $92.56 million whilst confirming FDA acceptance of New Drug Applications for ulixacaltamide in Essential Tremor and relutrigine in SCN2A/SCN8A epileptic encephalopathies. Target action dates are set for 2026 and 2027 respectively. The regulatory milestones advance two programmes into formal FDA review alongside ongoing trials for vormatrigine and elsunersen. The company maintains a cash runway into 2028 as it concentrates resources on its central nervous system pipeline. The narrative projects $724.1 million revenue and $89.5 million earnings by 2029, requiring 359.5% yearly revenue growth. Analysts' forecasts yield a $449.13 fair value, representing 31% upside to current prices, though the most optimistic projections estimate $2.1 billion revenue by 2029.

Yahoo Finance
May 12th, 2026
Wedbush raises Praxis Precision Medicines price target to $166 despite underperform rating

Wedbush maintained an "Underperform" rating on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) whilst raising its price target from $130 to $166, citing concerns about the ulixacaltamide filing and valuation. The FDA has accepted new drug applications for ulixacaltamide and relutrigine, with PDUFA dates of 29 January 2027 and 27 September 2026. Chief executive Marcio Souza said the company is positioning for two US launches within eight months. The clinical-stage biopharmaceutical company reported a net loss of $92.6 million for the quarter ending 31 March 2026. It holds approximately $1.4 billion in cash and investments, extending its financial runway into 2028. Additional clinical readouts are expected in 2026.

Yahoo Finance
May 3rd, 2026
Praxis ties executive pay to ulixacaltamide progress after 283% share gain and $567M raise

Praxis Precision Medicines has scheduled its 2026 annual meeting for 10 June to vote on director elections, auditor ratification and a Say-on-Pay proposal. The biotech company reported positive Phase 3 data for ulixacaltamide in essential tremor and filed an early new drug application. Praxis is implementing performance-based restricted stock units following a year that included a $567.1 million follow-on offering and a 283% share price gain. Vanguard Capital Management has taken a stake exceeding 5%, signalling institutional interest in management's incentive alignment. The company's narrative projects $724.1 million revenue and $89.5 million earnings by 2029, requiring 359.5% yearly revenue growth. Key near-term catalysts include FDA review of ulixacaltamide, whilst ongoing losses and potential dilution remain investor concerns.

Yahoo Finance
Mar 13th, 2026
Biotech Praxis secures $80.5M investment from Driehaus as stock soars 685% ahead of dual FDA filings

Driehaus Capital Management has invested $80.5 million in Praxis Precision Medicines, purchasing 432,510 shares and bringing its stake to 1.87% of assets under management. The transaction, disclosed on 17 February 2026, increased Driehaus's position value by $248.5 million, reflecting both the purchase and share price appreciation. Praxis shares have surged 685% over the past year to $303.37, giving the company an $8.4 billion market capitalisation. The biotech firm recently submitted two FDA applications: ulixacaltamide for essential tremor and relutrigine for rare developmental epilepsies. CEO Marcio Souza estimates the company's four late-stage programmes could generate over $20 billion in revenue if commercialised. Praxis ended 2025 with $926 million in cash and raised an additional $621 million in January, providing funding through 2028.

Intellectia AI
Feb 16th, 2026
Affinity Asset Advisors Acquires New Stake in Praxis Precision Medicines

- **New Investment Disclosure**: On February 13, 2026, Affinity Asset Advisors disclosed a new position by acquiring 185,000 shares of Praxis Precisio...